Supplemental Oxygen in Pulmonary Fibrosis

Completed

Conditions studied: Pulmonary Fibrosis

In brief

To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change from before to after supplemental oxygen is prescribed.

Key facts

Study ID

NCT01961362

Run by

National Jewish Health

People needed

19

Starts

2013-10-01

Expected to finish

2016-12-01

Last updated by the study team

2020-02-25

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patient-Participants
• (Using daily 02 therapy at time of enrollment)
• Diagnosis of PF
• Able to read and speak English
• Has been on daily-use supplemental oxygen for more than one year
• (Not using daily 02 therapy at time of enrollment)
• Diagnosis of PF
• Able to read, speak and write in English
• Has not been prescribed daily-use supplemental oxygen
• Forced vital capacity <75% and diffusing capacity <65% of predicted values
• Subject's physician allows the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection
• Primary Supporters
• Self-report status of providing care or support to a person living with pulmonary fibrosis who has used supplemental oxygen for more than one year
• Able to speak English
• O2 Prescribers
• Self-report status of being a prescriber of daily-use supplemental oxygen to PF patients
• Able to speak English

You may not qualify if…

• Patient-Participants (Using daily 02 therapy at time of enrollment)
• No diagnosis of PF
• Unable to read and speak English
• Has been on daily-use supplemental oxygen for less than one year
• (Not using daily 02 therapy at time of enrollment)
• No diagnosis of PF
• Unable to read, speak and write in English
• Using supplemental oxygen during the day
• Subject's physician does not allow the subject to abstain from daily-use supplemental oxygen for 7-10 days after prescription to allow data for collection
• Primary Supporters • Not meeting inclusion criteria
• O2 Prescribers
• Not meeting inclusion criteria

Where it is running

• National Jewish Health Interstitial Lung Disease Program — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.